Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats

Phytomedicine

Volumn 17, Issue 2, 2010, Pages 116-125

  El Shitany, Nagla A ^a   Hegazy, Sahar ^a   El desoky, Karema ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Ethinylestradiol; Hormone; Osteoporosis; Silymarin; Uterus

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CALCIUM; CHOLESTEROL; ESTRADIOL; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; FOLLITROPIN; LIPID; LUTEINIZING HORMONE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SILYMARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HISTOPATHOLOGY; MOLECULAR DOCKING; NONHUMAN; OSSIFICATION; OVARIECTOMY; PRIORITY JOURNAL; RAT; TRABECULAR BONE; UTERUS WEIGHT;

ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CALCIUM; ENDOMETRIAL HYPERPLASIA; ESTRADIOL; ESTROGEN RECEPTOR BETA; ETHINYL ESTRADIOL; FEMALE; HORMONES; LIPIDS; MILK THISTLE; ORGAN SIZE; OSTEOCALCIN; OSTEOPOROSIS; OVARIECTOMY; PHOSPHORUS; PHYTOESTROGENS; PHYTOTHERAPY; PLANT EXTRACTS; RATS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SILYMARIN; UTERUS; WEIGHT GAIN;

ANIMALIA; RATTUS; TRABECULA;

EID: 73449128972     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2009.05.012     Document Type: Article

References (49)

1. Arshad M., Sengupta S., Sharma S., Ghosh R., Sawlani V., and Singh M.M. In vitro anti-resorptive activity and prevention of ovariectomy-induced osteoporosis in female Sprague-Dawley rats by ormeloxifene, a selective estrogen receptor modulator. J. Steroid Biochem. Mol. Biol. 91 (2004) 67-78
2. Barnett R.N., Skodon S.B., and Goldberg M.H. Performance of kits used for clinical chemical analysis of calcium in serum. Am. J. Clin. Path. 59 (1973) 836-843
3. Bian Z., Nilsson S., and Gustafsson J.A. Selective estrogen receptor modulators and coronary heart disease. Trends Cardiovasc. Med 11 (2001) 196-202
4. Bonjour J.P., Ammann P., Chevalley T., and Rizzoli R. Protein intake and bone growth. Can. J. Appl. Physiol. 26 (2001) 153-166
5. Camacho-Hubner C., and Savage M. Insulin-like growth factor-I deficiency. Horm. Res. 55 (2001) 17-20
6. Chambers T.J. Regulation of the differentiation and function of osteoclasts. J. Pathol. 192 (2000) 4-13
7. Couse J.F., and Korach K.S. Estrogen receptor null mice: what have we learned and where will they lead us?. Endocr. Rev 20 (1999) 358-417
8. Crocenzi F.A., and Roma M.G. Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication. Curr. Med. Chem. 13 9 (2006) 1055-1074
9. Leo V., Ditto A., Marca A., Lanzetta D., Massafra C., and Morgante G. Bone mineral density and biochemical markers of bone turnover in peri- and postmenopausal women. Calcif. Tissue Int. 66 (2000) 263-267
10. Duarte B., Hargis G.K., and Kukreja S.C. Effects of estradiol and progesterone on parathyroid hormone secretion from human parathyroid tissue. J. Clin. Endocrinol. Metab. 66 (1988) 584-587
11. Felson D.T., Zhang Y., Hannan M.T., Kiel D.P., Wilson P.W., and Anderson J.J. The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 329 (1993) 1141-1146
12. Gamst O., and Try K. Determination of serum-phosphate without deproteinization by ultraviolet spectrophotometry of the phosphomolybdic acid complex. Scand. J. Clin. Lab. Invest. 40 (1980) 483-486
13. Gladkova A.I., and Karpenova N.A. Interrelationship of thyroid and sex functions in males. Probl. Endokrinol. (Mosk). 37 (1999) 56-59
14. Glidewell-Kenney C., Weiss J., Hurley L.A., Levine J.E., and Jameson J.L. Estrogen receptor alpha signaling pathways differentially regulate gonadotropin subunit gene expression and serum FSH in the female mouse. Endocrinology (2008) [Epub ahead of print]
15. Greenberg C., Kukreja S.C., Bowser E.N., Hargis G.K., Henderson W.J., and Williams G.A. Parathyroid hormone secretion: effect of estradiol and progesterone. Metabolism 36 2 (1987) 151-154
16. Heine P.A., Taylor J.A., Iwamoto G.A., Lubahn D.B., and Cooke P.S. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc. Natl. Acad. Sci. USA 97 23 (2000) 12729-12734
17. Hertrampf T., Gruca M.J., Seibel J., Laudenbach U., Fritzemeier K.H., and Diel P. The bone-protective effect of the phytoestrogen genistein is mediated via ERα- dependent mechanisms and strongly enhanced by physical activity. Bone 40 6 (2007) 1529-1535
18. Hertrampf T., Schleipen B., Velders M., Laudenbach U., Fritzemeier K.H., and Diel P. Estrogen receptor subtype-specific effects on markers of bone homeostasis. Mol. Cell. Endocrinol. 291 1-2 (2008) 104-108
19. Hidaka S., Okamoto Y., Uchiyama S., Nakatsuma A., Hashimoto K., Tsuyoshi Ohnishi S., and Yamaguchi M. Royal jelly prevents osteoporosis in rats: beneficial effects in ovariectomy model and in bone tissue culture model. eCAM 3 3 (2006) 339-348
20. Keshri G., Oberoi R.M., Lakshmi V., Pandey K., and Singh M.M. Contraceptive and hormonal properties of the stem bark of Dysoxylum binectariferum in rat and docking analysis of rohitukine, the alkaloid isolated from active chloroform soluble fraction. Contraception 76 (2007) 400-407
21. Kind P.R.N., and King E.J. Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine. J. Clin. Path. 7 (1954) 322-326
22. Knight J.A., Anderson S., and Rawlem J.M. Estimation of total lipids in serum and tissues. Clin. Chem. 18 (1972) 199-201
23. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., and Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. P.N.A.S 93 (1996) 5925-5930
24. Kummer V., Maskova J., Canderle J., Zraly Z., Neca J., and Machala M. Estrogenic effect of silymarin in ovariectomized rats. Vet. Med. Czech 46 1 (2001) 17-23
25. Levy C., Seeff L.D., and Lindor K.D. Use of herbal supplements for chronic liver disease. Clin. Gastroenterol. Hepatol. 2 (2004) 947-956
26. Lian J.B., Stein G.S., Canalis E., Robey P.G., and Boskey A.L. Bone Formation: Osteoblast Lineage Cells, Growth Factors, Matrix Proteins, and the Mineralization Process, Primer on the Metabolic Bone Diseases and Disorder of Mineral Metabolism (1999), Lippincott Williams and Wilkins, Philadelphia, PA pp. 14-29 (Chapter 3)
27. Lindberg M.K., Alatalo S.L., Halleen J.M., Mohan S., Gustafsson J.A., and Ohlsson C. Estrogen receptor specificity in the regulation of the skeleton in female mice. J. Endocrinol. 171 2 (2001) 229-236
28. McCarthy T.L., Ji C., and Centrella M. Links among growth factors, hormones, and nuclear factors with essential roles in bone formation. Crit. Rev. Oral Biol. Med. 11 (2000) 409-422
29. Naveh-Many T., Epstein E., and Silver J. Oestrogens and calcium regulatory hormones: potential implications for bone. Curr. Opin. Nephrol. Hypertens 4 4 (1995) 319-323
30. Nishikawa Y., Ikegami H., Sakata M., Mizutani T., Morishige K., Kurachi H., Hirota K., Miyake A., and Tanizawa O. Ovariectomy increases the level of estrogen receptor mRNA and estrogen receptor binding sites in female rat adipose tissue. J. Endocrinol. Invest. 16 8 (1993) 579-583
31. Ogawa S., Fujita M., Ishii Y., Tsurukami H., Hirabayashi M., Ikeda K., Orimo A., Hosoi T., Ueda M., Nakamura T., Ouchi Y., Muramatsu M., and Inoue S. Impaired estrogen sensitivity in bone by inhibiting both estrogen receptor alpha and beta pathway. J. Biol. Chem. 14 (2000) 21372-21379
32. Omi N., and Ezawa I. The effect of ovariectomy on bone metabolism in rats. Bone 17 (1995) 163S-168S
33. Pliskova M., Vondraacek J., Kren V., Gazak R., Sedmera P., Walterova D., Psotova J., Simanek V., and Machala M. Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology 215 (2005) 80-89
34. Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin. Chem. 19 12 (1973) 1350-1356
35. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. J.A.M.A 288 (2002) 321-333
36. Roudebush R.E., Magee D.E., Benslay D.N., Bendele A.M., and Bryant H.U. Effect of weight manipulation on bone loss due to ovariectomy and the protective effects of estrogen in the rat. Calcif. Tissue Int. 53 1 (1993) 61-64
37. Saunders P.T.K., Maguire S.M., Gaughan J., and Millar M.R. Expression of oestrogen receptor beta (ERβ) in multiple rat tissues visualized by immunohistochemistry. J. Endocrinol. 154 (1997) R13-R16
38. Seidlová-Wuttke D., Becker T., Christoffel V., Jarry H., and Wuttke W. Silymarin is a selective estrogen receptor β (ERβ) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in uterus of ovariectomized (ovx) rats. J. Steroid Biochem. Mol. Biol. 86 (2003) 179-188
39. Seidlová-Wuttke D., Hesse O., Jarry H., Christoffel V., Spengler B., Becker T., and Wuttke W. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Eur. J. Endocrinol. 149 4 (2003) 351-362
40. Smoller S.W. Biostatistics and Epidemiology: A Primer for Health and Biomedical Professionals. third ed. (2004), Springer-Verlag Inc., New York, USA pp. 69-77
41. Sonnenbichler J., Scalera F., Sonnenbichler I., and Weyhenmeyer R. Stimulatory effect of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J. Pharm. Exp. Ther 290 (1999) 1375-1383
42. Sonnenbichler J., and Zetl I. Specific binding of a flavonolignane derivative to an estradiol receptor. In: Cody V., Middleton E., Karbone J.B., and Berck A. (Eds). Progress in Clinical and Biological Research vol. 280 (1988), Alan R. Liss Inc., New York 369-374
43. Srivastava S., Toraldo G., Weitzmann M.N., Cenci S., Ross F.P., and Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J. Biol. Chem. 276 12 (2000) 8836-8840
44. Swaminathan R. Biochemical markers of bone turnover. Clin. Chim. Acta 313 (2001) 95-105
45. Tinwell H., Soames A.R., Foster J.R., and Ashby J. Estradiol-type activity of coumestrol in mature and immature ovariectomized rat uterotrophic assays. Environ. Health Prespect. 108 (2000) 631-634
46. Weiderpass E., Adami H.O., Baron J.A., et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J. Natl. Cancer Inst. 91 (1999) 1131-1137
47. Windahl S.H., Vidal O., Andersson G., Gustafsson J.A., and Ohlsson C. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ER-β-/- mice. J. Clin. Invest. 104 (1999) 895-901
48. Wronski T.J., Cintron M., Doherty A.L., and Dann L.M. Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology 123 (1988) 681-686
49. Yilmaz B., Seyran A.D., Sandal S., Aydin M., Colakoglu N., Kocer M., and Carpenter D.O. Modulatory effects of Aroclors 1221 and 1254 on bone turnover and vertebral histology in intact and ovariectomized rats. Toxicol. Lett. 166 (2006) 276-284